CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $523,209, lower than 95% of all stocks globally
- PositionCurrent ratio is 67.7×, higher than 95% of its Biotechnology peers (median 5.71×)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
429.50BKRW309.81M · vs all stocks (USD)
Revenue (TTM)
725.35MKRW523.21K · vs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.63xvs all stocks
52-Week Change
-32.60%vs all stocks
Market Capitalization
429.50BKRW309.81M · vs all stocks (USD)
Enterprise Value
347.64BKRW250.76M · vs all stocks (USD)
Forward P/E
-19.27xvs Biotechnology peers
Price to Book (MRQ)
4.45xvs Biotechnology peers
Enterprise to Revenue
479.27xvs Biotechnology peers
Enterprise to EBITDA
-38.84xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1324.10%vs Biotechnology peers
Return on Assets (TTM)
-6.14%vs Biotechnology peers
Return on Equity (TTM)
-9.65%vs Biotechnology peers
Revenue (TTM)
725.35MKRW523.21K · vs all stocks (USD)
Revenue per Share (TTM)
31.43KRWUpdated Sep 21, 2026Gross Profit (TTM)
700.23MKRW505.09K · vs all stocks (USD)
EBITDA (TTM)
-8.95BKRW-6.46M · vs all stocks (USD)
Net Income (TTM)
-9.01BKRW-6.50M · vs all stocks (USD)
Operating Cash Flow (TTM)
-4.67BKRW-3.37M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-8.66BKRW-6.25M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.17BKRWFY2025 · Dec 31, 2025Gross Profit
2.17BKRWFY2025 · Dec 31, 2025Operating Income
-7.26BKRW-5.24M · vs all stocks (USD)
Pre-tax Income
-9.73BKRWFY2025 · Dec 31, 2025Net Income
-9.73BKRWFY2025 · Dec 31, 2025EBIT
-9.11BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.00BKRWFY2025 · Dec 31, 2025Research & Development
4.02BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
754.73MKRWFY2025 · Dec 31, 2025Other Operating Expenses
116.76MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
3.33BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
618.94MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.73BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-11.21BKRWFY2025 · Dec 31, 2025Free Cash Flow
-11.50BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
7.07BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.73BKRWFY2025 · Dec 31, 2025Stock-based Compensation
1.14BKRWFY2025 · Dec 31, 2025Other Non-cash Items
-2.73BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
114.63MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.37MKRWFY2025 · Dec 31, 2025Capital Expenditures
-287.84MKRWFY2025 · Dec 31, 2025Purchase of Investments
-98.89BKRWFY2025 · Dec 31, 2025Sale of Investments
104.79BKRWFY2025 · Dec 31, 2025Other Investing Activity
113.98KKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
5.61BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.34MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
1.84BKRWFY2025 · Dec 31, 2025Shares Outstanding
23.34MSharesUpdated Sep 21, 2026Float Shares
17.88MSharesUpdated Sep 21, 2026% Held by Insiders
16.48%vs all stocks
% Held by Institutions
6.10%vs all stocks
Total Cash (MRQ)
80.73BKRW58.23M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.45KKRWUpdated Sep 21, 2026Total Debt (MRQ)
530.33MKRW382.53K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0055xvs Biotechnology peers
Current Ratio (MRQ)
67.70xvs Biotechnology peers
Book Value per Share (MRQ)
4.14KKRWUpdated Sep 21, 2026Total Assets
97.12BKRW70.05M · vs all stocks (USD)
Total Current Assets
94.71BKRWFY2025 · Dec 31, 2025Total Liabilities
803.77MKRWFY2025 · Dec 31, 2025Total Non-current Assets
2.41BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
262.25MKRWFY2025 · Dec 31, 2025Total Current Liabilities
541.52MKRWFY2025 · Dec 31, 2025Cash Equivalents
7.07BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
7.07BKRWFY2025 · Dec 31, 2025Other Short-term Investments
85.70BKRWFY2025 · Dec 31, 2025Short-term Debt
264.65MKRWFY2025 · Dec 31, 2025Other Current Liabilities
1.03KKRWFY2025 · Dec 31, 2025Long-term Debt
233.34MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
10.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
23.21BKRWFY2025 · Dec 31, 2025Retained Earnings
-82.08BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
96.32BKRW69.47M · vs all stocks (USD)
52-Week Low
16.45KKRWUpdated Sep 21, 202652-Week High
76.70KKRWUpdated Sep 21, 202652-Week Change
-32.60%vs all stocks
Beta
1.63xvs all stocks
50-Day MA
22.42KKRWUpdated Sep 21, 2026200-Day MA
46.43KKRWUpdated Sep 21, 2026Avg 10-Day Volume
126.02KSharesUpdated Sep 21, 2026Avg 30-Day Volume
250.69KSharesUpdated Sep 21, 2026Diluted EPS (TTM)
-429.00KRWUpdated Sep 21, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Liquidity Ratios Elevated
It can cover near-term bills from cash alone, not just from inventory.
Reads
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 67.7×, higher than 95% of its Biotechnology peers (median 5.71×)Significant
Current ratio: 67.70Industry median: 5.71Industry P95: 22.21Peers compared: 260
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $523,209, lower than 95% of all stocks globallySignificant
Revenue (USD): 523,209.474Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abeona Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
CytoDyn Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Evommune, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Won Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lavipharm S.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Shenzhen JDD Tech New Material Co., Ltd.
5 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration
Beijing Tricolor Technology Co., Ltd.
5 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownLiquidity Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedLow-Leverage Liquidity Configuration
Kratos Defense & Security Solutions, Inc.
4 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownLiquidity Ratios ElevatedLow-Leverage Liquidity Configuration